These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 18398612)
1. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Erlich RB; Rickwood D; Coman WB; Saunders NA; Guminski A Cancer Chemother Pharmacol; 2009 Feb; 63(3):381-9. PubMed ID: 18398612 [TBL] [Abstract][Full Text] [Related]
2. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor. Mandic R; Rodgarkia-Dara CJ; Krohn V; Wiegand S; Grénman R; Werner JA Anticancer Res; 2009 Apr; 29(4):1181-7. PubMed ID: 19414362 [TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Mace AT; Harrow SJ; Ganly I; Brown SM Acta Otolaryngol; 2007 Aug; 127(8):880-7. PubMed ID: 17763002 [TBL] [Abstract][Full Text] [Related]
5. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Krishna S; Brown N; Faller DV; Spanjaard RA Laryngoscope; 2002 Apr; 112(4):645-50. PubMed ID: 12150517 [TBL] [Abstract][Full Text] [Related]
6. Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation. Záskodová D; Rezácová M; Vávrová J; Vokurková D; Tichy A Ann N Y Acad Sci; 2006 Dec; 1091():385-98. PubMed ID: 17341630 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Rossi MJ; Sundararaj K; Koybasi S; Phillips MS; Szulc ZM; Bielawska A; Day TA; Obeid LM; Hannun YA; Ogretmen B Otolaryngol Head Neck Surg; 2005 Jan; 132(1):55-62. PubMed ID: 15632910 [TBL] [Abstract][Full Text] [Related]
8. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Gao D; Xia Q; Lv J; Zhang H Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752 [TBL] [Abstract][Full Text] [Related]
9. Antileukemic activity of the combination of ionizing radiation with valproic acid in promyelocytic leukemia cells HL-60. Rezacova M; Zaskodova D; Vavrova J; Vokurkova D; Tichy A Neoplasma; 2008; 55(6):519-25. PubMed ID: 18999881 [TBL] [Abstract][Full Text] [Related]
10. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. Kanao K; Mikami S; Mizuno R; Shinojima T; Murai M; Oya M J Urol; 2008 Sep; 180(3):1131-6. PubMed ID: 18639283 [TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300 [TBL] [Abstract][Full Text] [Related]
12. 7beta-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma. Heiduschka G; Erovic BM; Vormittag L; Skoda C; Martinek H; Brunner M; Ehrenberger K; Thurnher D Arch Otolaryngol Head Neck Surg; 2009 Mar; 135(3):261-7. PubMed ID: 19289704 [TBL] [Abstract][Full Text] [Related]
13. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756 [TBL] [Abstract][Full Text] [Related]
14. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Wang D; Veena MS; Stevenson K; Tang C; Ho B; Suh JD; Duarte VM; Faull KF; Mehta K; Srivatsan ES; Wang MB Clin Cancer Res; 2008 Oct; 14(19):6228-36. PubMed ID: 18829502 [TBL] [Abstract][Full Text] [Related]
15. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Neri P; Tagliaferri P; Di Martino MT; Calimeri T; Amodio N; Bulotta A; Ventura M; Eramo PO; Viscomi C; Arbitrio M; Rossi M; Caraglia M; Munshi NC; Anderson KC; Tassone P Br J Haematol; 2008 Nov; 143(4):520-31. PubMed ID: 18986388 [TBL] [Abstract][Full Text] [Related]
16. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells. Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. Ferguson PJ J Otolaryngol; 1995 Aug; 24(4):242-52. PubMed ID: 8551538 [TBL] [Abstract][Full Text] [Related]
19. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in Vitro. Erjala K; Pulkkinen J; Kulmala J; Alanen K; Grenman R Anticancer Res; 2002; 22(6A):3135-42. PubMed ID: 12530056 [TBL] [Abstract][Full Text] [Related]
20. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of fusaric acid and paclitaxel or carboplatin. Jaglowski JR; Stack BC Cancer Lett; 2006 Nov; 243(1):58-63. PubMed ID: 16412572 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]